Status:

COMPLETED

The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity

Lead Sponsor:

University Medical Centre Ljubljana

Conditions:

Type 2 Diabetes Mellitus

Obesity

Eligibility:

MALE

18-65 years

Phase:

PHASE3

Brief Summary

The goal of this study is to learn whether semaglutide (treatment for type 2 diabetes and obesity) can improve signs and symptoms of hypogonadism in men with type 2 diabetes, obesity and hypogonadism ...

Detailed Description

Men aged 18 - 65 years with type 2 diabetes on oral antidiabetic treatment, body mass index above 30 kg/m2 and functional hypogonadism (total testosterone below 11 nmol/L and at least 2 symptoms of hy...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • type 2 diabetes mellitus,
  • obesity (body mass index (BMI) higher or equal to 30 kg/m\^2),
  • functional hypogonadism (defined by total testosterone less than 11 nmol/L and 2 or more symptoms of sexual dysfunction)
  • Exclusion criteria:
  • Insulin treatment,
  • glucagon-like peptide 1 (GLP-1) agonist treatment,
  • sodium-glucose cotransporter-2 (SGLT-2) inhibitor treatment,
  • other identified causes of hypogonadism,
  • hemochromatosis,
  • active malignant disease,
  • thrombophilia,
  • venous thrombosis within 6 months,
  • recent acute myocardial infarction or stroke,
  • prostate-specific antigen (PSA) higher than 3 ng/L,
  • severe lower urinary tract symptoms with an International Prostate Symptom Score above 19,
  • severe sleep apnea syndrome,
  • hematocrit higher than 0.5,
  • significant kidney or liver disease,
  • ongoing treatment with opioid analgesics, antipsychotics, glucocorticoids,
  • alcohol abuse,
  • severe ongoing mental illness,
  • personal history of pancreatitis or medullary thyroid carcinoma,
  • personal or family history of multiple endocrine neoplasia type 2.

Exclusion

    Key Trial Info

    Start Date :

    September 20 2020

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    June 30 2023

    Estimated Enrollment :

    25 Patients enrolled

    Trial Details

    Trial ID

    NCT06489457

    Start Date

    September 20 2020

    End Date

    June 30 2023

    Last Update

    July 8 2024

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    University Medical Centre Ljubljana

    Ljubljana, Slovenia, 1000

    The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity | DecenTrialz